PPT-Ticagrelor compared with clopidogrel in patients with acute

PLAT elet Inhibition and patient O utcomes trial Outcomes in patients with a Planned Invasive Strategy The PLATO trial was funded by AstraZeneca Invasive PLATO background In STEMI and UANSTEMI current guidelines recommend 12 months of aspirin and clopidogrel. Antiplatelet Guidelines. PERIOPERATIVE MANAGEMENT OF ANTIPLATELET THERAPY. Working Group: . James D. Douketis MD, FRCP(C); A. Graham . Turpie. MD, FRCP(C). Objectives. Interpret the Canadian Cardiovascular Society . presented by . Paul St. Laurent, MSN, RN, ACNP, CCRN. Acute Care Nurse Practitioner. Baylor Heart and Vascular Hospital. What Do We Already Know?. Aspirin reduces the risk of myocardial infarction. Antiplatelet therapy reduces stent thrombosis. Acute Coronary Syndromes and Diabetes. Chapter 26. Jean-Claude Tardif, Phillipe L. L’Allier,. David H. Fitchett. Acute Coronary Syndrome Checklist. SCREEN. for DM among patients with ACS. USE . anti-platelet therapies, . د. حسين محمد جمعة . اختصاصي الامراض الباطنة . البورد العربي . كلية طب الموصل . 2010. National Institute for Health and Clinical Excellence guidelines. Therapy for Secondary Prevention . Beyond One Year . Following . ACS or PCI. Working Group. : . Anil Gupta MD, FRCPC, Pierre Theroux MD, FRCPC . Canadian Cardiovascular Society Antiplatelet Guidelines. safety study . of . ticagrelor's. degradation combining . LC-MS and . in . silico. approach. H. SADOU YAYE*, B. DO, N. YAGOUBI. * . Pharmacist at . Pitié-Salpêtrière. Hospital (Paris) . P. hD student – University Paris . Ticagrelor. for Secondary Prevention: . Insights from PEGASUS-TIMI 54 Trial . Marc P. . Bonaca. , MD, MPH. on behalf of the . PEGASUS-TIMI 54 . Executive & Steering Committees and Investigators. Management of NSTE-ACS Dr shahinlal ACS v/s Chronic stable angina Sudden onset of symptoms at rest/ minimal exertion At least lasting for 10 min unless treated promptly. Severe pain/ pressure/discomfort in chest Associate Professor of Clinical Pharmacy,. SBMU. CLASSIFICATION OF ANTIPLATELET AGENTS. Cyclooxygenase inhibitors. Aspirin. Platelet . P2Y12 receptor . blockers. clopidogrel, . ticlopidine. , . ticagrelor. coronary intervention PCI1920 As new antithrombotic drugs DABE in combination with ticagrelor oers an additional option to substitute warfarin regimen with the expectation of decreasing the bleeding r �� ��NDA 20-839 / S-044 Page 6 dosing. After a single, oral dose of 75 mg, clopidogrel has a half-life of approximately 6 hours. The elimination half-life of the i Luis Ortega-Paz, MD, PhD. 1. ; Francesco Franchi, MD. 1. ; Fabiana Rollini, MD1, Mattia Galli, MD. 1. ,. 2. Latonya Been, AAS. 1. , Ghussan Ghanem, MD. 1. , . Awss. . Shalhoub. , MD. 1. , Tiffany Ossi, MD. (n . = 6,589). SOCRATES. Primary outcome, death, MI or stroke, for ticagrelor vs. aspirin: . 6.7% . vs. 7.5%, HR = 0.89, 95% CI . 0.78-1.01. , . p = 0.07. Death: 1.0% vs. 0.9%, . p = 0.36; All . strokes: 5.9% vs. 6.8%, . Malhar Agarwal, MD, Megha Kureti, MD, Deepa Nagaraju, MD, Mustafa . Wali. , MD, . Zubair. Shaikh, MD, . Maryuri. . Briceno. , MD, Ahmed Nawaz, MD, Jae Youn Moon, MD, . PhD, Latonya . Been, AAS, Siva Suryadevara, MD, Daniel Soffer, MD, Martin M Zenni, .